Drug intelligence / Profile preview

ABY-1220

Development stage: Unknown
Lead developer: Abyssinia Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ABY-1220 is a monoclonal antibody drug candidate developed by Abyssinia Biologics. It acts as an inhibitor of the beta amyloid A4 protein (APP), targeting the pathological accumulation of beta amyloid in the brain—a hallmark of Alzheimer’s disease. The drug is being investigated for its potential to treat nervous system diseases, with a primary focus on Alzheimer’s disease. As of June 2025, it remains in the discovery phase and has not yet entered clinical trials or received regulatory approval[1][2].

Targets

Aβ oligomers (Amyloid-β oligomers)

Beyond the preview

Go deeper on ABY-1220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABY-1220.

Explore the full profile